|
Real-time Estimate
Cboe BZX
02:37:35 2026-10-29 pm EDT
|
5-day change | 1st Jan Change | ||
| 161.55 USD | +1.48% |
|
+2.63% | +31.43% |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 197,401 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 29.63% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 218,673 | 211,020 | 203,984 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 28.95% | -3.5% | -3.33% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -45.8x | 19.7x | 18.1x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 13.9x | 9.82x | 7.48x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.03x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.42x | 6x | 5.71x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 7.11x | 6.42x | 5.9x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 27.5x | 11.5x | 10.8x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 67.2x | 13.1x | 11.9x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | -415x | 14.7x | 14.7x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | -0.24% | 6.82% | 6.8% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.297 | 3.358 | 3.077 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 2.07% | 2.11% | 1.93% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -3.477 | 8.083 | 8.805 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -94.8% | 41.5% | 34.9% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 30,765 | 32,893 | 34,601 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 7,938 | 18,367 | 18,821 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 3,256 | 16,053 | 17,119 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -4,375 | 10,282 | 10,920 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 21,272 | 13,619 | 6,583 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 159.20 | 159.20 | 159.20 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,239,955 | - | - |
| Announcement Date | 2/1/22 | 2/2/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | ||
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | ||
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | ||
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | ||
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | ||
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | ||
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | ||
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | ||
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | ||
| 11.16x | 4.11x | 8.42x | 4.5% | 168B | ||
| Average | 27.72x | 6.81x | 17.80x | 2.35% | 420.54B | |
| Weighted average by Cap. | 34.32x | 8.22x | 20.15x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
















